<DOC>
	<DOCNO>NCT00872846</DOCNO>
	<brief_summary>To evaluate safety performance BALANCE System treat patient type 2 diabetes overweight . Impact blood glucose level , weight loss , blood pressure clinical metabolic parameter study .</brief_summary>
	<brief_title>Balance System Study Type 2 Diabetic Patients</brief_title>
	<detailed_description>The BALANCE System stimulate duodenum specialized way strengthen natural contraction mimic sensation fullness ( satiety ) . The patient expect feel full eat small amount food normal . In addition , duodenal stimulation show induce favorable change postprandial glucose level , glucose tolerance test insulin level . The target population type II diabetic patient uncontrolled oral medication , overweight ( BMI &gt; 30 ) . The Balance System may overcome know disadvantage insulin therapy allow early treatment patient , potentially prevent progression obesity diabetes .</detailed_description>
	<criteria>Type 2 Diabetes inadequately control maximum three oral antidiabetic agent HbA1c 7 10 % inclusive Fasting Blood Glucose 126 200 mg/dL Body Mass Index ( BMI ) range 30.0 45.0 kg/m2 Stable oral antidiabetic therapy least 3 month Subjects able willing perform self monitor plasma glucose entire trial period Able willing sign inform consent return followup assessment Type 1 Diabetes Subjects high risk general anesthesia surgery Subjects prior pancreatitis Subjects treat insulin within three month screen Female positive pregnancy test , plan become pregnant screening , active treatment , follow period , breastfeeding , judge use inadequate contraceptive method . Subjects underwent previous intra abdominal , GI tract surgery major abdominal trauma . Subjects implanted electrical stimulation device Subjects motility disorder GI tract gastroparesis Subjects receiving medication know affect gastric motility Subjects history peptic ulcer disease Subjects serious health condition , cancer , cardiac disease , immunodeficiency disorder , liver disease , pulmonary disease , renal insufficiency , coagulopathy major depressive disorder . Subjects severe diabetic complication , retinopathy nephropathy Subjects metabolic endocrine disorder like primary secondary Cushing syndrome Subjects receive another investigational agent within 30 day prior screen Evidence current recent alcohol drug abuse within past year prior screen Subjects unlikely available followup specify protocol Subjects past present psychiatric condition may impair ability comply study procedure Subjects history volvulus Subjects history know small bowel adhesion know GI adhesion Subjects deficiencies know vitamin , e.g . B12 Subjects know celiac disease inflammatory bowel disease Subjects condition , judgment investigator , preclude successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Body weight</keyword>
	<keyword>Signs symptom</keyword>
	<keyword>Obesity</keyword>
	<keyword>Metabolic disease</keyword>
	<keyword>Diabetes mellitus type 2</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Nutrition disorder</keyword>
	<keyword>Endocrine system disease</keyword>
	<keyword>Overweight</keyword>
	<keyword>Overnutrition</keyword>
	<keyword>Glucose metabolic disorder</keyword>
</DOC>